X ( Announces Upcoming Interview With CEO of RxElite

Tuesday, August 28, 2007 General News J E 4
MERIDIAN, Idaho, Aug. 27 Southridge Technology Group, Inc.(OTC Bulletin Board: SOUT) and RxElite Holdings, Inc., its wholly ownedoperating subsidiary, a developer, manufacturer, and marketer of specialtygeneric prescription drug products, announced today that Daniel Chen, CEO,RxElite will be featured live in an exclusive interview with www.wallst.netthat is scheduled to take place on August 29 at 12:00 p.m. EDT. The interviewwill be posted on by 8 p.m. EDT on August 29.

The interview will cover topics including RxElite's market potential,growth initiatives, competitive edge, recent news, and milestones for whichinvestors should watch. To hear the interview in its entirety, visit, and click on "Interviews." The interview can beaccessed either by locating the company's ticker symbol under the appropriateexchange on the left-hand column of the "Interviews" section of the site, orby entering the company's ticker symbol in the Search Archive window once itis posted.

About RxElite Holdings, Inc.

RxElite Holdings, Inc. develops, manufactures, and markets genericprescription drug products in specialty generic markets. These markets includeproducts in the areas of anesthesia, sterile liquid dose drugs (includingrespiratory inhalation drugs, ophthalmics, and injectable drugs), andtransdermal patch products.

The full details of the transactions described in this press release canbe found in our filings with the Securities and Exchange Commission.

For interviews with RxElite CEO Daniel Chen, or for inquiries related toinvestor relations, please contact Charlie Forshee at 215-885-4981.

SOURCE Financial Filings Corp.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Saving Lives of California Residents Who Develop S...
Diamyd Updates Gene Therapy Program and Outlines P...